Oral Oncology
Volume 40, Issue 7 , Pages 679-687 , August 2004

Characteristics of antitumor activity of mutant type p27Kip1 gene in an oral cancer cell line

  • Supriatno

      Affiliations

    • Second Department of Oral and Maxillofacial Surgery, School of Dentistry, University of Tokushima, 3-18-15 Kuramoto-cho, Tokushima 770-8504, Japan
    • ,
  • Koji Harada

      Affiliations

    • Second Department of Oral and Maxillofacial Surgery, School of Dentistry, University of Tokushima, 3-18-15 Kuramoto-cho, Tokushima 770-8504, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81-88-633-7354; fax: +81-88-633-7462
    • ,
  • Shin-ichi Kawaguchi

      Affiliations

    • Department of Oral and Maxillofacial Radiology, School of Dentistry, University of Tokushima, 3-18-15 Kuramoto-cho, Tokushima 770-8504, Japan
    • ,
  • Tomitaro Onoue

      Affiliations

    • Second Department of Oral and Maxillofacial Surgery, School of Dentistry, University of Tokushima, 3-18-15 Kuramoto-cho, Tokushima 770-8504, Japan
    • ,
  • Hideo Yoshida

      Affiliations

    • Second Department of Oral and Maxillofacial Surgery, School of Dentistry, University of Tokushima, 3-18-15 Kuramoto-cho, Tokushima 770-8504, Japan
    • ,
  • Mitsunobu Sato

      Affiliations

    • Second Department of Oral and Maxillofacial Surgery, School of Dentistry, University of Tokushima, 3-18-15 Kuramoto-cho, Tokushima 770-8504, Japan

Received 25 November 2003 ,Accepted 18 December 2003.

References 

  1. Hall M, Peters G. Genetic alterations of cyclins, cyclin-dependent kinases, and cdk inhibitors in human cancer. Adv. Cancer Res. 1996;68:67–108
  2. Grana X, Reddy EP. Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene. 1995;11:211–219
  3. Sherr CJ, Roberts JM. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 1995;9:1149–1163
  4. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999;13:1501–1512
  5. Polyak K, Kato JY, Solomon MJ, Sherr CJ, Massague J, Roberts JM, et al.  p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-and contact inhibition to cell cycle arrest. Genes Dev. 1994;8:9–22
  6. Polyak K, Lee MH, Erdjument-Bromage H, Koff A, Roberts JM, Tempst P, et al.  Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell. 1994;78:59–66
  7. Catzavelos C, Bhattacharya N, Ung YC, Wilson JA, Roncari L, Sandhu C, et al.  Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nature Med. 1997;3:227–230
  8. Esposito V, Baldi A, De Luca A, Groger AM, Loda M, Giordano GG, et al.  Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res. 1997;57:3381–3385
  9. Mori M, Mimori K, Shiraishi T, Tanaka S, Ueo H, Sugimachi K, et al.  p27 expression and gastric carcinoma. Nature Med. 1997;3:593
  10. Mineta H, Miura K, Suzuki I, Takebayashi S, Amano H, Araki K, et al.  Low p27 expression correlates with poor prognosis for patients with oral tongue squamous cell carcinoma. Cancer. 1999;85:1011–1107
  11. Supriatno , Harada K, Kawaguchi S, Yoshida H, Sato M. Effect of p27Kip1 on the ability of invasion and metastasis of an oral cancer cell line. Oncol. Rep. 2003;10:527–532
  12. Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, et al.  Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nature Med. 1997;2:231–234
  13. Kawamata N, Morosetti R, Miller CW, Park D, Spirin KS, Nakamaki T, et al.  Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies. Cancer Res. 1995;55:2266–2269
  14. Montagnoli A, Fiore F, Eytan E, Carrano AC, Draetta GF, Hershko A, et al.  Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation. Genes Dev. 1999;13:1181–1189
  15. Vlach J, Hennecke S, Amati B. Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27Kip1. EMBO J. 1997;16:5334–5344
  16. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB. Evaluation of a tetrazolium-based semiautomated calorimetric assay: assessment of chemosensitivity testing. Cancer Res. 1987;47:936–942
  17. Chen X, Ko LJ, Jayaraman L, Prives C. p53 levels, functional domains, and DNA damage determine the extents of the apoptotic response of tumor cells. Genes Dev. 1996;10:2438–2451
  18. Nakayama K, Ishida N, Shirane M, Inomata A, Inoue T, Shishido N, et al.  Mice lacking p27Kip1 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell. 1996;85:707–720
  19. St Croix B, Florenes VA, Rak JW, Flanagan M, Bhattacharya N, Slingerland JM, et al.  Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anti-cancer agents. Nature Med. 1996;2:1204–1210
  20. Katayose Y, Kim M, Rakkar ANS, Li Z, Cowan KH, Seth P. Promoting apoptosis: a novel activity associated with the cyclin-dependent kinase inhibitor p27. Cancer Res. 1997;57:5441–5445
  21. Ophascharoensuk V, Fero ML, Hughes J, Roberts JM, Shankland SJ. The cyclin-dependent kinase inhibitor p27Kip1 safeguards against inflammatory injury. Nature Med. 1998;4:575–580
  22. Durand B, Gao FB, Raff M. Accumulation of the cyclin-dependent kinase inhibitor p27/Kip1 and the timing of oligodendrocyte differentiation. EMBO J. 1997;16:306–317
  23. Clurman BE, Porter P. New insights into tumor suppression function of p27Kip1. Proc. Natl. Acad. Sci. USA. 1998;95:15158–15160
  24. Fero ML, Rivkin M, Tasch M, Porter P, Carow CE, Firpo E, et al.  A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27Kip1-deficient mice. Cell. 1996;85:733–744
  25. Fero ML, Randel E, Gurley KE, Roberts JM, Kemp CJ. The murine gene p27Kip1 is haplo-insufficient for tumor suppression. Nature (Lond.). 1998;386:177–180
  26. Craig C, Wersto R, Kim M, Ohri E, Li Z, Katayose D, et al.  A recombinant adenovirus expressing p27Kip1 induces cell cycle arrest and loss of cyclin-Cdk activity in human breast cells. Oncogene. 1997;14:2283–2289
  27. Rakkar AN, Li Z, Katayose Y, Kim M, Cowan KH, Seth P. Adenoviral expression of the cyclin-dependent kinase inhibitor p27Kip1: a strategy for breast cancer gene therapy. J. Natl. Cancer Inst. 1998;90:1836–1838
  28. Park KH, Seol JY, Yoo CG, Kim YW, Han SK, Lee EH, et al.  Adenovirus expressing p27Kip1 induces growth arrest of lung cancer cell lines and suppresses the growth of established lung cancer xenografts. Lung Cancer. 2001;31:149–155
  29. Supriatno , Harada K, Hoque MO, Bando T, Yoshida H, Sato M. Overexpression of p27Kip1 induces growth arrest and apoptosis in an oral cancer cell line. Oral Oncol. 2002;38:730–736
  30. Park KH, Seol JY, Kim TY, Yoo CG, Kim YW, Han SK, et al.  An adenovirus expressing mutant p27 showed more potent antitumor effects than adenovirus-p27 wild type. Cancer Res. 2001;61:6163–6169
  31. Koh TY, Park SW, Park KH, Lee SG, Seol JG, Lee DW, et al.  Inhibitory effect of p27Kip1 gene transfer on head and neck squamous cell carcinoma cell lines. Head Neck. 2003;25:44–49
  32. Kudo Y, Kitajima S, Sato S, Ogawa I, Miyauchi M, Takata T. Transfection of p27Kip1 threonine residue 187 mutant type gene, which is not influenced by ubiquitin-mediated degradation, induces cell cycle arrest in oral squamous cell carcinoma cells. Oncology. 2002;63:398–404
  33. Naruse I, Hoshino H, Dobashi K, Minato K, Saito R, Mori M. Overexpression of p27Kip1 induces growth arrest and apoptosis mediated by changes of pRb expression in lung cancer cell lines. Int. J. Cancer. 2000;88:377–383
  34. Wang X, Gorospe M, Huang Y, Holbrook NJ. p27Kip1 overexpression causes apoptotic death of mammalian cells. Oncogene. 1997;15:2991–2997
  35. Schreiber M, Muller WJ, Singh G, Graham FL. Comparison of the effectiveness of adenovirus vectors expressing cyclin kinase inhibitors p16INK4A, p18INK4C, p19INK4D, p21WAF/CIP1 and p27Kip1 in inducing cell cycle arrest, apoptosis and inhibition of tumorigenicity. Oncogene. 1999;18:1663–1676
  36. Hiromura K, Pippin JW, Fero ML, Roberts JM, Shankland SJ. Modulation of apoptosis by the cyclin-dependent kinase inhibitor p27Kip1. J. Clin. Invest. 1999;103:597–604

PII: S1368-8375(04)00006-5

doi: 10.1016/j.oraloncology.2004.01.002

Oral Oncology
Volume 40, Issue 7 , Pages 679-687 , August 2004

Article Tools

* Image Usage & Resolution